Compile Data Set for Download or QSAR
Report error Found 224 Enz. Inhib. hit(s) with all data for entry = 10373
TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531296(US11208399, Example 53)
Affinity DataIC50: 0.400nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531223(US11208399, Example 4 | (R)-2-(4-Methyl-6-((1-meth...)
Affinity DataIC50: 0.400nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531253(US11208399, Example 12)
Affinity DataIC50: 0.600nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531331(US11208399, Example 82)
Affinity DataIC50: 0.700nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531289(US11208399, Example 48)
Affinity DataIC50: 0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531332(US11208399, Example 83a)
Affinity DataIC50: 0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531220(US11208399, Example 1 | (R)-2-(6-((1-Ethylpiperidi...)
Affinity DataIC50: 0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531288(US11208399, Example 47)
Affinity DataIC50: 0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531319(US11208399, Example 71)
Affinity DataIC50: 0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531230(US11208399, Example 6)
Affinity DataIC50: 0.900nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531254(US11208399, Example 13)
Affinity DataIC50: 1.20nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531337(US11208399, Example 85b | 3-Methyl-2-(6-(((1R,2R,5...)
Affinity DataIC50: 1.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531252(US11208399, Example 11)
Affinity DataIC50: 1.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531354(US11208399, Example 94a | 2-(6-(((3S, 5S)-5-Fluoro...)
Affinity DataIC50: 1.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531291(US11208399, Example 49)
Affinity DataIC50: 1.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531339(US11208399, Example 86b | 2-(6-(((1S,2S,5S)-8-(2-H...)
Affinity DataIC50: 1.80nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531232(US11208399, Example 7)
Affinity DataIC50: 1.90nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531364(US11208399, Example 101 | (R)-2-(6-((1-Ethylpiperi...)
Affinity DataIC50: 1.90nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531292(US11208399, Example 50)
Affinity DataIC50: 2.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531323(US11208399, Example 74)
Affinity DataIC50: 2.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531293(US11208399, Example 51)
Affinity DataIC50: 2.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531282(US11208399, Example 41)
Affinity DataIC50: 3nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531224(US11208399, Example 5 | (R)-3-Methyl-2-(5-methyl-6...)
Affinity DataIC50: 3nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531279(US11208399, Example 39)
Affinity DataIC50: 3.20nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531286(US11208399, Example 45)
Affinity DataIC50: 3.20nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531350(US11208399, Example 92a | 2-(6-(((R)-1-((S)-2-Hydr...)
Affinity DataIC50: 3.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531318(US11208399, Example 70)
Affinity DataIC50: 3.5nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531351(US11208399, Example 92b | 2-(6-(((R)-1-((R)-2-Hydr...)
Affinity DataIC50: 3.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531329(US11208399, Example 80)
Affinity DataIC50: 4.70nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531310(US11208399, Example 64)
Affinity DataIC50: 5.90nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531363(US11208399, Example 100 | (R)-3-Methyl-2-(5-methyl...)
Affinity DataIC50: 6nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531340(US11208399, Example 87a | 2-(6-(((3R,6R)-6-(Hydrox...)
Affinity DataIC50: 6.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531352(US11208399, Example 93a | 2-(6-(((3S,5S)-5-Fluorop...)
Affinity DataIC50: 6.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531280(US11208399, Example 40)
Affinity DataIC50: 6.80nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531311(US11208399, Example 65)
Affinity DataIC50: 7.40nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531360(US11208399, Example 97 | (3S,5R)-5-((6-(2-Hydroxy-...)
Affinity DataIC50: 7.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531302(US11208399, Example 56)
Affinity DataIC50: 8.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531221(US11208399, Example 2 | 2-(6-(((cis)-3-Hydroxy-3-m...)
Affinity DataIC50: 10.2nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531299(US11208399, Example 54)
Affinity DataIC50: 11.8nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531356(US11208399, Example 95a | 2-(6-(((3S, 5R)-5-Fluoro...)
Affinity DataIC50: 13nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531324(US11208399, Example 75)
Affinity DataIC50: 18.3nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531309(US11208399, Example 63)
Affinity DataIC50: 22.7nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531237(US11208399, Example 8)
Affinity DataIC50: 24.1nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531283(US11208399, Example 42)
Affinity DataIC50: 25.3nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531222(US11208399, Example 3 | 2-(6-(((1R,3S)-3-Hydroxycy...)
Affinity DataIC50: 25.5nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531359(US11208399, Example 96b | 2-(6-(((3R, 5S)-5-Fluoro...)
Affinity DataIC50: 26nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531258(US11208399, Example 17)
Affinity DataIC50: 33.1nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531305(US11208399, Example 59)
Affinity DataIC50: 35.9nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531257(US11208399, Example 16)
Affinity DataIC50: 36.3nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

TargetInterleukin-1 beta(Human)
Novartis

US Patent
LigandPNGBDBM531313(US11208399, Example 67)
Affinity DataIC50: 40.1nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2022
Entry Details
US Patent

Displayed 1 to 50 (of 224 total ) | Next | Last >>
Jump to: